Major domestic drug firms to report 8-10% revenue growth in current fiscal: Icra
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Icra has said leading domestic pharmaceutical companies are expected to report a revenue growth of 8-10 per cent in the current fiscal (FY24). It expects growth of its sample set of 25 companies, which account for 60 per cent of the overall Indian pharmaceutical industry, to sustain at 8-10 per cent in FY24. This is likely to be supported by continued price increases, new product launches and rising penetration of healthcare services in semi-urban and rural areas.
It further stated despite several disruptive events over the last few years, the domestic drug market witnessed a healthy CAGR (Compound Annual Growth Rate) of 9.7 per cent between FY14 and FY23. Growth in recent years has largely been supported by price increases and new product introductions even as volume growth has been negative or 2-3 per cent at best.
Besides, it said that acute therapies, accounting for 62-65 per cent of the pharma industry, have continued to outpace growth in chronic therapies since FY22. However, the trend is expected to reverse going forward. Moreover, it said ‘With increasing incidence of lifestyle diseases and given the long duration of medicine courses for chronic diseases, the growth of chronic therapies in the IPM (Indian Pharmaceutical Market) is expected to be higher than that of acute therapies.’
